These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30190962)

  • 1. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers.
    Golfieri R
    Hepat Oncol; 2014 Jun; 1(3):265-283. PubMed ID: 30190962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.
    Lee EJ; Chung HW; Jo JH; So Y
    Nucl Med Mol Imaging; 2019 Dec; 53(6):367-373. PubMed ID: 31867071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
    Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
    JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
    Cappelli A; Pettinato C; Golfieri R
    J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.
    Bhangoo MS; Karnani DR; Hein PN; Giap H; Knowles H; Issa C; Steuterman S; Pockros P; Frenette C
    J Gastrointest Oncol; 2015 Oct; 6(5):469-78. PubMed ID: 26487939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
    Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes Analysis of 90Y Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the RESiN (Radiation-Emitting SIR-spheres in Non-resectable liver tumors) Registry.
    Zhou W; Du L; Brown DB; Shah RP; Sze DY
    J Vasc Interv Radiol; 2024 Jul; ():. PubMed ID: 39009301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.
    Lewandowski RJ; Salem R
    Semin Intervent Radiol; 2006 Mar; 23(1):64-72. PubMed ID: 21326721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases.
    Wang C; Park J; Ouyang C; Longmate JA; Tajon M; Chao J; Lim D; Sandhu J; Yin HH; Pillai R; Gozo MC; Avalos C; Egelston CA; Lee PP; Fakih M
    Oncologist; 2020 May; 25(5):382-e776. PubMed ID: 31857446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolization for primary and metastatic liver cancer.
    Memon K; Lewandowski RJ; Kulik L; Riaz A; Mulcahy MF; Salem R
    Semin Radiat Oncol; 2011 Oct; 21(4):294-302. PubMed ID: 21939859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization for the treatment of unresectable liver cancer: initial experience at a single center.
    Peynircioğlu B; Cil B; Bozkurt F; Aydemir E; Uğur O; Balkanci F
    Diagn Interv Radiol; 2010 Mar; 16(1):70-8. PubMed ID: 20180183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
    Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
    J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies.
    Kennedy AS; Salem R
    Cancer J; 2010; 16(2):163-75. PubMed ID: 20404614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.